Literature DB >> 24762283

Laboratory testing for factor inhibitors.

E J Favaloro1, B Verbruggen, C H Miller.   

Abstract

Inhibitor assays are performed when patients present with unexplained prolonged routine coagulation test times and unexpected and/or unusual bleeding (potential for acquired haemophilia) as well as being a part of normal congenital haemophilia management and monitoring, particularly when bleeding occurs on therapy, or when increments in factor levels post-factor replacement remain lower than expected. In this article, we will describe the assays used, as well as their development, pitfalls in testing such as inter-laboratory variability and false negative/positive results, as well as some strategies for overcoming these pitfalls and potential alternative test approaches. The inter-laboratory coefficient of variation often approaches (and sometimes exceeds) 50%, as evidenced by various external quality assessment groups, and this variability has not improved over recent years. Additional important considerations include appropriate interpretation of test results, repeat testing for confirmation, and assessment of recovery as part of the diagnostic process.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  assay variation; diagnostic accuracy; factor inhibitors; fluorescence immunoassay; haemophilia; low titre inhibitors

Mesh:

Substances:

Year:  2014        PMID: 24762283     DOI: 10.1111/hae.12408

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Improving the performance of factor VIII inhibitor tests in hemophilia A.

Authors:  Connie H Miller
Journal:  Thromb Res       Date:  2015-09-28       Impact factor: 3.944

Review 2.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

3.  Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Authors:  C H Miller; B Boylan; A D Shapiro; S R Lentz; B M Wicklund
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

4.  Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report.

Authors:  Saša Anžej Doma; Andreas Hillarp; Tadej Pajič; Dušan Andoljšek; Peter Černelč; Irena Preldžnik Zupan
Journal:  Biochem Med (Zagreb)       Date:  2016       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.